Noam Solomon and Luis Voloch (Immunai)

Wad­ing deep­er in­to tar­get dis­cov­ery and val­i­da­tion, Im­mu­nai bags $60M to beef up both AI al­go­rithms and lab bench­es

Noam Solomon and Luis Voloch set out, when they launched Im­mu­nai in 2018, to map out the im­mune sys­tem cell by cell.

The two en­gi­neers — who had met at MIT and like to il­lus­trate their com­pa­ny’s stature by point­ing out the num­ber of em­ploy­ees who had been trained at Palan­tir, Google or Face­book — saw the po­ten­tial in col­lat­ing all the in­for­ma­tion churned out by a sin­gle cell-se­quenc­ing mul­ti-omics plat­form. You can tell drug­mak­ers what ex­act­ly is in their cell ther­a­py prod­ucts, pro­file for aca­d­e­mics the im­mune re­sponse to their ex­per­i­men­tal treat­ments, or even sug­gest new bio­mark­ers that seem to be rel­e­vant in a dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.